A synthetic biology approach to probing nucleosome symmetry

  1. Yuichi Ichikawa
  2. Caitlin F Connelly
  3. Alon Appleboim
  4. Thomas C Miller
  5. Hadas Jacobi
  6. Nebiyu A Abshiru
  7. Hsin-Jung Chou
  8. Yuanyuan Chen
  9. Upasna Sharma
  10. Yupeng Zheng
  11. Paul M Thomas
  12. Hsuiyi V Chen
  13. Vineeta Bajaj
  14. Christoph W Müeller
  15. Neil L Kelleher
  16. Nir Friedman
  17. Daniel NA Bolon
  18. Oliver J Rando  Is a corresponding author
  19. Paul D Kaufman  Is a corresponding author
  1. University of Massachusetts Medical School, United States
  2. The Hebrew University, Israel
  3. European Molecular Biology Laboratory (EMBL), Germany
  4. Northwestern University, United States

Abstract

The repeating subunit of chromatin, the nucleosome, includes two copies of each of the four core histones, and recent studies have reported that asymmetrically-modified nucleosomes occur at regulatory elements in vivo. To probe the mechanisms by which histone modifications are read , we designed an obligate pair of H3 heterodimers, termed H3X and H3Y, which we extensively validated genetically and biochemically. Comparing effects of asymmetric histone tail point mutants with those of symmetric double mutants revealed that a single methylated H3K36 per nucleosome was sufficient to silence cryptic transcription in vivo. We demonstrate the utility of this system for analysis of histone modification crosstalk, using mass spectrometry to separately identify modifications on each H3 molecule within asymmetric nucleosomes. The ability to generate asymmetric nucleosomes in vivo and in vitro provides a powerful and generalizable tool to probe the mechanisms by which H3 tails are read by effector proteins in the cell.

Article and author information

Author details

  1. Yuichi Ichikawa

    Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Caitlin F Connelly

    Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Alon Appleboim

    School of Computer Science and Engineering, The Hebrew University, Jerusalem, Israel
    Competing interests
    The authors declare that no competing interests exist.
  4. Thomas C Miller

    Structural and Computational Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Hadas Jacobi

    School of Computer Science and Engineering, The Hebrew University, Jerusalem, Israel
    Competing interests
    The authors declare that no competing interests exist.
  6. Nebiyu A Abshiru

    National Resource for Translational and Developmental Proteomics, Northwestern University, Evanston, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Hsin-Jung Chou

    Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Yuanyuan Chen

    Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Upasna Sharma

    Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Yupeng Zheng

    National Resource for Translational and Developmental Proteomics, Northwestern University, Evanston, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Paul M Thomas

    National Resource for Translational and Developmental Proteomics, Northwestern University, Evanston, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Hsuiyi V Chen

    Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Vineeta Bajaj

    Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Christoph W Müeller

    Structural and Computational Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  15. Neil L Kelleher

    National Resource for Translational and Developmental Proteomics, Northwestern University, Evanston, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8815-3372
  16. Nir Friedman

    School of Computer Science and Engineering, The Hebrew University, Jerusalem, Israel
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9678-3550
  17. Daniel NA Bolon

    Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  18. Oliver J Rando

    Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, United States
    For correspondence
    Oliver.Rando@umassmed.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1516-9397
  19. Paul D Kaufman

    Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, Worcester, United States
    For correspondence
    paul.kaufman1@umassmed.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3089-313X

Funding

National Institute of General Medical Sciences (R01GM100164)

  • Yuichi Ichikawa
  • Caitlin F Connelly
  • Hsin-Jung Chou
  • Hsuiyi V Chen
  • Oliver J Rando
  • Paul D Kaufman

European Commission (340712)

  • Alon Appleboim
  • Hadas Jacobi
  • Nir Friedman

National Institute of General Medical Sciences (P41GM108569)

  • Nebiyu A Abshiru
  • Yupeng Zheng
  • Paul M Thomas
  • Neil L Kelleher

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2017, Ichikawa et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,768
    views
  • 520
    downloads
  • 20
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yuichi Ichikawa
  2. Caitlin F Connelly
  3. Alon Appleboim
  4. Thomas C Miller
  5. Hadas Jacobi
  6. Nebiyu A Abshiru
  7. Hsin-Jung Chou
  8. Yuanyuan Chen
  9. Upasna Sharma
  10. Yupeng Zheng
  11. Paul M Thomas
  12. Hsuiyi V Chen
  13. Vineeta Bajaj
  14. Christoph W Müeller
  15. Neil L Kelleher
  16. Nir Friedman
  17. Daniel NA Bolon
  18. Oliver J Rando
  19. Paul D Kaufman
(2017)
A synthetic biology approach to probing nucleosome symmetry
eLife 6:e28836.
https://doi.org/10.7554/eLife.28836

Share this article

https://doi.org/10.7554/eLife.28836

Further reading

    1. Chromosomes and Gene Expression
    2. Microbiology and Infectious Disease
    Maruti Nandan Rai, Qing Lan ... Koon Ho Wong
    Research Article Updated

    Candida glabrata can thrive inside macrophages and tolerate high levels of azole antifungals. These innate abilities render infections by this human pathogen a clinical challenge. How C. glabrata reacts inside macrophages and what is the molecular basis of its drug tolerance are not well understood. Here, we mapped genome-wide RNA polymerase II (RNAPII) occupancy in C. glabrata to delineate its transcriptional responses during macrophage infection in high temporal resolution. RNAPII profiles revealed dynamic C. glabrata responses to macrophages with genes of specialized pathways activated chronologically at different times of infection. We identified an uncharacterized transcription factor (CgXbp1) important for the chronological macrophage response, survival in macrophages, and virulence. Genome-wide mapping of CgXbp1 direct targets further revealed its multi-faceted functions, regulating not only virulence-related genes but also genes associated with drug resistance. Finally, we showed that CgXbp1 indeed also affects fluconazole resistance. Overall, this work presents a powerful approach for examining host-pathogen interaction and uncovers a novel transcription factor important for C. glabrata’s survival in macrophages and drug tolerance.

    1. Chromosomes and Gene Expression
    2. Neuroscience
    Robyn D Moir, Emilio Merheb ... Ian M Willis
    Research Article

    Pathogenic variants in subunits of RNA polymerase (Pol) III cause a spectrum of Polr3-related neurodegenerative diseases including 4H leukodystrophy. Disease onset occurs from infancy to early adulthood and is associated with a variable range and severity of neurological and non-neurological features. The molecular basis of Polr3-related disease pathogenesis is unknown. We developed a postnatal whole-body mouse model expressing pathogenic Polr3a mutations to examine the molecular mechanisms by which reduced Pol III transcription results primarily in central nervous system phenotypes. Polr3a mutant mice exhibit behavioral deficits, cerebral pathology and exocrine pancreatic atrophy. Transcriptome and immunohistochemistry analyses of cerebra during disease progression show a reduction in most Pol III transcripts, induction of innate immune and integrated stress responses and cell-type-specific gene expression changes reflecting neuron and oligodendrocyte loss and microglial activation. Earlier in the disease when integrated stress and innate immune responses are minimally induced, mature tRNA sequencing revealed a global reduction in tRNA levels and an altered tRNA profile but no changes in other Pol III transcripts. Thus, changes in the size and/or composition of the tRNA pool have a causal role in disease initiation. Our findings reveal different tissue- and brain region-specific sensitivities to a defect in Pol III transcription.